Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation

References

• Begg AC, Stewart FA, Vens C. 2011. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11:239–253.
   PubMed Web of Science ®Google Scholar
• Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R. 2012. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 7:154.
   PubMed Web of Science ®Google Scholar
• Cao J, Zhang J, Wang Z, Wang B, Lv F, Wang L, Hu X. 2014. Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer. Cancer Chemother Pharmacol 74:389–398.
   PubMed Web of Science ®Google Scholar
• Chan AT, Leung SF, Ngan RKC, Teo PML, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, et al. 2005. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer I 97:536–539.
   PubMed Web of Science ®Google Scholar
• Chung HW, Wen J, Lim JB, Bang S, Park SW, Song SY. 2009. Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. Int J Radiat Oncol Biol Phys 75:862–869.
   PubMed Web of Science ®Google Scholar
• Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB. 2008. SU11248 (Sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71:873–879.
   PubMed Web of Science ®Google Scholar
• Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. 2007. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395–3402.
   PubMed Web of Science ®Google Scholar
• EI Kaffas A, Al-Mahrouki A, Tran WT, Giles A, Czarnota GJ. 2014. Sunitinib effects on the radiation response of endothelial and breast tumor cells. Microvasc Res 92:1–9.
   PubMed Web of Science ®Google Scholar
• Folkman J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18.
   PubMed Web of Science ®Google Scholar
• Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. 1993. Expression and prognostic significance of platelet- derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550–4554.
   PubMed Web of Science ®Google Scholar
• Jalal Hosseinimehr S, Inanami O, Hamasu T, Takahashi M, Kashiwakura I, Asanuma T, Kuwabara M. 2004. Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in HL60 cells. J Radiat Res 45:557–561.
   PubMed Web of Science ®Google Scholar
• Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al. 2005. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107–1116.
   PubMed Web of Science ®Google Scholar
• Li M, Ping G, Plathow C, Trinh T, Lipson KE, Hauser K, Krempien R, Debus J, Abdollahi A, Huber PE. 2006. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer 6:79.
   PubMed Web of Science ®Google Scholar
• Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. 2003. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 21:631–637.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen LH, Yuan YW, Li QS, Sun AM, Guan J. 2012. Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumor Biol 33:241–245.
   PubMed Web of Science ®Google Scholar
• Lu B, Shinohara ET, Edwards E, Geng L, Tan J, Hallahan DE. 2005. The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy. Technol Cancer Res Treat 4:691–698.
   PubMed Web of Science ®Google Scholar
• McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. 2003. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22:5866–5875.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global Cancer Statistics, 2002. CA-Cancer J Clin 55:74–108.
   PubMed Web of Science ®Google Scholar
• Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE. 2013. Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res 73:1611–1620.
   PubMed Web of Science ®Google Scholar
• Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, et al. 2011. Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 17:1815–1827.
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich RK. 2003. Molecular targets in radiation oncology. Oncogene 22:5730–5733.
   PubMed Web of Science ®Google Scholar
• Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. 2003. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63:4009–4016.
   PubMed Web of Science ®Google Scholar
• Wang SS, Guan ZZ, Xiang YQ, Wang B, Lin TY, Jiang WQ, Zhang L, Zhang HZ, Hou JH. 2006. Significance of EGFR and p-ERK expression in nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 28:28–31.
   PubMedGoogle Scholar
• Yaren A, Oztop I, Kargi A, Ulukus C, Onen A, Sanli A, Binicier O, Yilmaz U, Alakavuklar M. 2006. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract 60:675–682.
   PubMed Web of Science ®Google Scholar
• Zhang HP, Takayama K, Su B, Jiao XD, Li R, Wang JJ. 2011. Effect of Sunitinib combined with ionizing radiation on endothelial cells. J Radiat Res 52:1–8.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhou AP, Qin Q, Chang CX, Jiang HY, Chakravarthy AB. 2013. Famitinib in metastatic renal cell carcinoma: A single center study. Chin Med J (Engl) 126:4277–4281.
   PubMed Web of Science ®Google Scholar
• Zhou AP, Zhang W, Chang C, Chen X, Zhong D, Qin Q, Lou D, Jiang H, Wang J. 2013. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol 72:1043–1053.
   PubMed Web of Science ®Google Scholar
• Zhou AP, Zhang W, Chang C, Chi Y, Wang J. 2011. Tolerability of famitinib malate: The preliminary results from phase I clinical trial. Chin J New Drugs 20:1678–1690.
   Google Scholar